COMMUNIQUÉS West-GlobeNewswire

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/02/2026
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
06/02/2026
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for [...]
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
06/02/2026
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE [...]
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
06/02/2026
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001) All [...]
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
06/02/2026
PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease Topline results on track for second half [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026
06/02/2026
VALNEVA Déclaration d’actions et de droits de vote 31 janvier 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
VALNEVA Declaration of shares and voting rights: January 31, 2026
06/02/2026
VALNEVA Declaration of shares and voting rights January 31, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
HUTCHMED to Announce 2025 Final Results
06/02/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, [...]
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
06/02/2026
Allschwil, Switzerland – February 06, 2026 Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings [...]
Coloplast A/S - Interim Financial Report, Q1 2025/26
06/02/2026
2025/26 Interim financial results, Q1 2025/26 1 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%- [...]
Chiral raises $12M to unlock post-silicon computing beyond Moore’s Law
06/02/2026
ZURICH, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Chiral , a Swiss nanotechnology company pioneering next-generation semiconductor and quantum technologies with nanomaterials, today announced the successful closing of a $12 [...]
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
06/02/2026
An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, [...]
Anaptys Announces Participation at Upcoming Investor Conferences
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
CooperCompanies Announces Release Date for First Quarter 2026
05/02/2026
SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4: [...]
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
05/02/2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Teladoc Health to Announce Fourth Quarter 2025 Financial Results
05/02/2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2026, after the [...]
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
05/02/2026
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative [...]
Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26
05/02/2026
CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026
06/02/2026
An informational overview examining compounded semaglutide vs FDA-approved GLP-1 medications, telehealth platform evaluation criteria, and what consumers consider when researching prescription weight management [...]

Pages